SSY Group Limited Secures Market Authorization for Ceftizoxime Sodium for Injection in China
Key Milestone in Product Development Potentially Impacting Share Value
SSY Group Limited (the Company, together with its subsidiaries, the Group) has announced a significant development in its pharmaceutical product portfolio. The Group has received official approval from the National Medical Products Administration of China (NMPA) to become the market authorization holder for Ceftizoxime Sodium for Injection in both 1g and 0.5g dosages.
Key Highlights
- Regulatory Approval: The NMPA has approved the Group as the market authorization holder for Ceftizoxime Sodium for Injection, granting SSY Group the exclusive right to market and distribute this product in China.
-
Product Applications: Ceftizoxime Sodium for Injection is a broad-spectrum antibiotic used to treat:
- Lower respiratory tract infections
- Urinary tract infections
- Abdominal and pelvic infections
- Sepsis
- Skin and soft tissue infections
- Bone and joint infections caused by susceptible bacteria
- Meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae
- Uncomplicated gonorrhea
- Strategic Impact: Securing this authorization strengthens SSY Group’s presence in the anti-infective market and broadens its product portfolio, potentially opening new revenue streams in China’s large antibiotics market.
- Corporate Governance: The announcement was signed by Mr. Chow Hing Yeung (Executive Director and Company Secretary) and confirms the composition of the Board, which includes experienced executive, non-executive, and independent non-executive directors.
Material Information for Shareholders and Potential Price Sensitivity
This development is potentially price sensitive as it may impact SSY Group’s financial performance by expanding its portfolio with a new, NMPA-approved antibiotic product. The ability to market and distribute Ceftizoxime Sodium for Injection could lead to increased market share, enhanced revenues, and an improved competitive position in the Chinese pharmaceutical sector. Investors should monitor further announcements regarding the product’s commercial launch, sales figures, and market reception for additional impact on share value.
Board of Directors
The Board comprises:
- Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong (Executive Directors)
- Mr. Liu Wenjun (Non-executive Director)
- Mr. Wang Yibing, Mr. Chow Kwok Wai, Mr. Jiang Guangce (Independent Non-executive Directors)
Announcement Date:
8 June 2026, Hong Kong
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions. The information is based on the latest public announcement by SSY Group Limited and may be subject to change.
